NEUROMYELITIS OPTICA SPECTRUM DISORDER
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in rare nerve disease trial
Disease control CompletedThis Phase 3 trial tested the drug ravulizumab (Ultomiris) in 58 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. The goal was to see if the drug could prevent relapses. Participants rec…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Soliris safety checked in korean patients
Knowledge-focused CompletedThis study looked at how safe and effective the drug Soliris is for Korean patients with a rare disease called NMOSD. It involved 11 people who were already taking the drug as part of their normal medical care. The goal was to track side effects and see if the drug helped prevent…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC